Y-Intercept (HK)
NRIX icon

Y-Intercept (HK)’s Nurix Therapeutics NRIX Stock Holding History

Y-Intercept (HK)’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-192,434
Closed -$4.67M – 1937
2026
Q2 		$4.67M Buy
192,434
+137,296
+249% +$2.34M 0.09% 302
2026
Q1 		$855K Buy
+55,138
New +$914K 0.02% 1091
2025
Q4 		– Sell
-55,231
Closed -$510K – 1862
2025
Q3 		$510K Buy
+55,231
New +$574K 0.01% 1252
2025
Q2 		– Sell
-31,458
Closed -$374K – 1896
2025
Q1 		$374K Buy
+31,458
New +$526K 0.03% 827
2024
Q4 		– Sell
-15,388
Closed -$346K – 1507
2024
Q3 		$346K Buy
+15,388
New +$349K 0.02% 949

Other funds holding NRIX

WestHill Financial Advisors
WestHill Financial Advisors San Rafael, California $597M AUM 13.09% 1-Year Est. Return
RAM Investment Partners
RAM Investment Partners Bellevue, Washington $631M AUM 11.73% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Root Financial Partners
Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Y-Intercept (HK)'s NRIX Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Nurix Therapeutics (NRIX) in Q3 2026, closing a stake of 192,434 shares — an estimated $4.67M sold.

Y-Intercept (HK) first reported a position in NRIX in Q3 2024 and held it in 5 quarters. The position peaked at $4.67M in Q2 2026. 14 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Y-Intercept (HK) reported no remaining Nurix Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 192,434 Nurix Therapeutics shares in Q3 2026, an estimated $4.67M.
  • Y-Intercept (HK) first reported a position in Nurix Therapeutics in Q3 2024 and held it in 5 quarters.
  • Y-Intercept (HK)'s Nurix Therapeutics position peaked at $4.67M in Q2 2026.
  • 14 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.